|
1: Nebulised treatments
|
Nebulised anticholinergics and/or beta2 agonists. Less frequently, nebulised corticosteroids.
|
|
One of the first two treatments was prescribed to 45.55% of patients.
|
|
2: Fixed combinations
|
Combinations of long acting beta 2 agonist and corticosteroids.
|
|
These combinations were prescribed to 51.44% of patients.
|
|
3 : LABA and inhaled corticosteroids prescribed separately
|
LABA and inhaled corticosteroids, co-prescribed in 91.2% of patients who receive one and/or the other outside of a fixed combination.
|
|
Such “separate associations” were prescribed to 16.03% of patients.
|
|
4: Non-invasive ventilation and oxygen therapy
|
Ventilation or oxygen therapy. Respiratory support may be prescribed with respiratory rehabilitation.
|
|
One of the first two therapies was prescribed to 18.71% of patients.
|
|
5: Fixed combinations of short-acting anticholinergic and β2 agonist
|
These treatments are not prescribed in patients who receive long acting anticholinergics. Prescription of a fixed combination of LABA and ICS is possible and independent (neither association nor exclusion).
|
|
These fixed combinations were prescribed to 29.85% of patients.
|
|
6: Flu and pneumococcal vaccines
|
Flu or pneumococcal vaccines and antibiotics, sometimes associated with chest physiotherapy.
|
|
At least one of the two first vaccines and antibiotics were prescribed to 39.83% of patients.
|
